	Application No.	Applicant(s)
Notice of Allowability	10/049,904	MIYACHI ET AL.
	Examiner	Art Unit
	Rebecca L Anderson	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>23 September 2003.</u>		
2. The allowed claim(s) is/are 1-7,20 and 21, now renumbered 1-9.		
 3. ☐ The drawings filed on are accepted by the Examiner. 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
 5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. (a) The translation of the foreign language provisional application has been received. 6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No 		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).		
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1 Notice of References Cited (PTO-892)	5☐ Notice of Informal Pat	tent Application (PTO-152)
2 Notice of Draftperson's Patent Drawing Review (PTO-948)	6⊠ Interview Summary (F	PTO-413), Paper No. <u>1206</u> .
3⊠ Information Disclosure Statements (PTO-1449 or PTO/SB/08)	7⊠ Examiner's Amendme	ent/Comment
Paper No. 23 Sept 03, 11 \$20€ 2002. 4☐ Examiner's Comment Regarding Requirement for Deposit	8X Examiner's Statement	t of Reasons for Allowance
of Biological Material	9 ☐ Other	

Application/Control Number: 10/049,904

Art Unit: 1626

DETAILED ACTION

Claims 1-7, 20 and 21 are currently pending in the instant application, are allowable over the prior art of record and have been renumbered as claims 1-9. Claim 21 drawn to a process for the preparation of a medicinal composition of claim 1 has been rejoined.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Tom Barnes on 3 December 2003.

The application has been amended as follows:

Specification:

1. Insert --This application is a 371 of PCT/JP00/05521 filed 18 August 2000.-- below the line that states "Technical Field" and above the line that states "The present invention relates to substituted" found on page 1 of the instant specification.

Claims:

- 1. Cancel claims 11-19.
- 2. Amend claim 21 by inserting --for preparing a medicinal composition--after "A process" and before the comma on line 1 of claim 21.
 - 3. Cancel claim 22.

Application/Control Number: 10/049,904 Page 3

Art Unit: 1626

Information Disclosure Statement

The information disclosure statement (IDS) submitted on 27 May 2003 discloses the copending application 10/049645. This co-pending application has been considered but will not be printed on the front of a patent issuing off of this application.

Oath/Declaration

The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because: It does not identify the citizenship of each inventor.

Specifically, the citizenship for Masahiro Nomura is missing in the oath.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance. This invention relates to benzylthiazolidine-2,4-dione products. The novel and nonobvious aspect of this invention involves the substituent A which is a phenyl, phenoxy or benzyloxy group. The closest prior art of record fails to teach or suggest the instant benzylthiazolidine-2,4-dione products which have an unexpected activity on PPAR alpha and/or unexpected dual agonist activity on PPAR alpha and gamma.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Application/Control Number: 10/049,904

Art Unit: 1626

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (703) 605-1157. Mrs. Anderson can normally be reached Monday through Friday 6:00AM to 2:30PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph McKane, can be reached at (703) 308-4537.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone numbers are (703) 308-1235 and (703) 308-0196.

A facsimile center has been established. The hours of operation are Monday through Friday, 8:45AM to 4:45PM. The telecopier number for accessing the facsimile machine is (703) 872-9306.

Rebecca Anderson Patent Examiner Art Unit 1626, Group 1620

Technology Center 1600

Joseph McKane Supervisory Patent Examiner Art Unit 1626, Group 1620 Technology Center 1600